Info

MMM Auto

21 59 (45-75)

Oral busulfan

5% 14% NA

Anemia response 10/17 Platelet response 4/8 Spleen response 7/10

HSCT, hematopoietic stem cell transplantation; NRM, nonrelapse mortality; GvHD, graft-versus-host disease; AMM, agnogenic myeloid metaplasia; MMM, myelofibrosis with myeloid metaplasia; PPMM, postpolycythemic myeloid metaplasia; PTMM, postthrombocythemic myeloid metaplasia; VOD, veno-occulsive disease; Allo, allogeneic stem cell transplant; ALT, alternative donor (i.e., matched unrelated, hap-loidentical); Bu, busulfan; Cy, cyclophosphamide; TBI, total body irradiation.

HSCT, hematopoietic stem cell transplantation; NRM, nonrelapse mortality; GvHD, graft-versus-host disease; AMM, agnogenic myeloid metaplasia; MMM, myelofibrosis with myeloid metaplasia; PPMM, postpolycythemic myeloid metaplasia; PTMM, postthrombocythemic myeloid metaplasia; VOD, veno-occulsive disease; Allo, allogeneic stem cell transplant; ALT, alternative donor (i.e., matched unrelated, hap-loidentical); Bu, busulfan; Cy, cyclophosphamide; TBI, total body irradiation.

0 0

Post a comment